metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology OP- 4 EPIDEMIOLOGY OF PRIMARY BILIARY CHOLANGITIS IN LATIN AMERICA: PRELIMINARY ...
Información de la revista
Vol. 29. Núm. S3.
Abstracts of the 2023 Annual Meeting of the ALEH
(diciembre 2024)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 29. Núm. S3.
Abstracts of the 2023 Annual Meeting of the ALEH
(diciembre 2024)
Acceso a texto completo
OP- 4 EPIDEMIOLOGY OF PRIMARY BILIARY CHOLANGITIS IN LATIN AMERICA: PRELIMINARY RESULTS FROM ALLATIN COHORT
Visitas
11
Guilherme Grossi Lopes Cançado1, Rafael Theodoro1, Ezequiel Ridruejo2, Lorena Castro Solari3, Cristiane Alves Villela-Nogueira4, Pablo Andres Coste Murillo5, Harlim Rodríguez6, Carlos Benítez Gajardo7, Álvaro Urzúa8, Eira Cerda Reyes9, Paulo Lisboa Bittencourt10, Alejandro Sosa11, Emilia Vera12, Luciana Costa Faria1, Maria Lucia Ferraz13, Mario Guimarães Pessoa14, Debora Raquel Benedita Terrabuio14, Eduardo Luiz Rachid Cançado14, Claudia Alves Couto1
1 Universidade Federal de Minas Gerais, Belo Horizonte, Brasil
2 Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno, Buenos Aires, Argentina
3 Clinica Universidad de Los Andes, Santiago, Chile
4 Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brasil
5 Hospital R. A. Calderón Guardia, San José, Costa Rica
6 Instituto de Gastroenterología de Cuba, Habana, Cuba
7 UC Christus, Santiago, Chile
8 Universidad de Chile, Santiago, Chile
9 Hospital Militar Central México, Ciudad de México, México
10 Hospital Portugues, Salvador, Brasil
11 Pontificia Universidad Católica de Chile, Santiago, Chile
12 Hospital Regional Guayaquil, Guayaquil, Ecuador
13 Universidade Federal de São Paulo, São Paulo, Brasil
14 Universidade de São Paulo, São Paulo, Brasil
Ver más
Este artículo ha recibido
Información del artículo
Suplemento especial
Este artículo forma parte de:
Vol. 29. Núm S3

Abstracts of the 2023 Annual Meeting of the ALEH

Más datos
Conflict of interest

No

Introduction and Objectives

Primary biliary cholangitis (PBC) may present differently depending on various factors such as ethnicity and genetic background. Latin America has a highly admixed population with a unique genetic diversity compared to other regions of the world. However, there is limited information available on the presentation and epidemiology of PBC in this region. This study aims to address the epidemiology of PBC in Latin America.

Patients / Materials and Methods

Ongoing retrospective, international, multicentric cohort study sponsored by ALEH that enrolls PBC patients from different countries in Latin America.

Results and Discussion

Data were accrued on 231 patients [Brazil (52%), Argentina (27.4%), Chile (10.8%), Costa Rica (4.5%), Cuba (3.6%), and Mexico (0.9%)], 92.1% female (mean age at diagnosis 50.5 years), 25.6% with cirrhosis at baseline. Overlap with autoimmune hepatitis was reported in 16.0% of cases. Most patients were symptomatic (67.9%) at diagnosis, with fatigue (41.9%) and pruritus (40.5%) being the main symptoms. Anti-mitochondrial antibodies (AMA) were positive in 70.8% and antinuclear antibodies (ANA) in 60.6%. Hashimoto thyroiditis (23.7%) and Sjogren syndrome (9.1%) were the most common extrahepatic autoimmune diseases associated with PBC. Mean baseline alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, and bilirubin levels were 445.9 (± 407), 89.8 (± 137.2), 37.6 (± 8.9) U/L, and 1.6 (± 3.1) mg/dL, respectively. Almost all patients (99.1%) were treated with ursodeoxycholic acid (UDCA). 67.4% achieved adequate response to UDCA according to the Toronto criteria and 32% normalized alkaline phosphatase at 12 months. Only 19.9% received second-line therapy, all with fibrates (89.1% bezafibrate, 8.7% ciprofibrate, 4.3% fenofibrate). Of the patients, 9% died, with 33% of deaths being liver-related, while 6% underwent liver transplantation. Hepatocellular carcinoma was diagnosed in 1.7% of patients.

Conclusions

In this unprecedented study, the epidemiology of PBC in Latin America appears similar to that in other parts of the world. However, lower rates of AMA positivity were observed, and most patients were still diagnosed with symptomatic disease. Second-line therapy options were limited to the availability of fibrates only.

El Texto completo está disponible en PDF
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos